Trial Profile
The comparative study about the efficacy and safety of alternative DPP-4 (dipeptidyl peptidase-4) inhibitor sitagliptin and the rapid-acting insulin secretagogue (glinide) in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2011
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Mitiglinide; Nateglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SINGLE
- 27 Apr 2011 New trial record